Healthcare U.S. Diabetes Pipeline Outlook

 

INDUSTRY
Healthcare
SECTOR
Life Sciences

RELEASE DATE
22-Nov-2006
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
N097-01-00-00-00
SKU
HC02005-NA-MR_07295
Yes
SHARE

U.S. Diabetes Pipeline Outlook
Published on: 22-Nov-2006 | SKU: HC02005-NA-MR_07295

Need more details?
$4,950.00
DownloadLink
Need more details?

This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.

Executive Summary

  • Introduction

Research Scope and Methodology

  • Scope and Segmentation
  • Research Methodology

Diabetes Overview

  • Introduction
  • Types of Diabetes
  • Prevalence
  • Incidence
  • Current Treatment

Pipeline Competitive Analysis

  • Introduction
  • Key Pipeline Companies
  • Areas of Opportunity

Introduction

GLP-1 Agonists Pipeline Analysis

Introduction

Pulmonary Insulin Analysis

Introduction

DPP-IV Pipeline Analysis

Introduction

PPAR Pipeline Analysis

Introduction

Pipeline Overviews

Decision Support Databases


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

07 Sep 2026   |   Global   |   Technology Research

Synthetic Antibodies and AI-Optimized Immunotherapies

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...

28 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

26 Aug 2026   |   Global   |   Technology Research

Growth Opportunities and Advancements in Acute and Chronic Wound Care

A wound is any disruption in the normal structure and function of the skin or underlying tissues. It can result from physical injury, surgery, or underlying medical conditions. Wounds are broadly classified into two categories: acute wounds and chronic wounds. Acute wounds typically heal through the...

26 Aug 2026   |   Global   |   Frost Radar

Frost Radar™: Healthcare Infrastructure Cybersecurity in the United States, 2026

Healthcare organizations are expanding their digital environments across cloud infrastructure, connected medical devices, applications, identities, operational technology, and distributed care settings, creating a broader and increasingly interconnected attack surface. Cybersecurity is, therefore, e...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.
More Information
Deliverable Type Market Research
No Index No
Podcast No
Industries Healthcare
WIP Number N097-01-00-00-00
Is Prebook No

U.S. Diabetes Pipeline Outlook

$4,950.00
In stock
SKU
HC02005-NA-MR_07295